

MANDATORY NOTIFICATION OF TRADE PRIMARY INSIDERS

Chairman of the board of NattoPharma ASA ("NattoPharma") and primary insider, Frode Marc Bohan, and his related parties, including TG Montgomery AS ("TGM"), have earlier irrevocably pre-accepted, if made and completed, the voluntarily offer (the "Offer") that Compagnie des Levures Lesaffre ("Lesaffre") is due to launch with an offer period that will commence on or prior to 19 March 2021, cf. the press release dated 15 February 2021 regarding the Offer and NattoPharma ASA's stock exchange notice dated 25 February 2021 regarding amendments to the Offer.

Today Frode Marc Bohan's related party TGM has agreed to purchase 330 360 shares (the "Additional Shares") in NattoPharma at a price of NOK 38 per share, subject to the Offer being completed. TGM's pre-acceptance of the Offer covers any shares TGM owned the date TGM gave its irrevocable pre-acceptance to Lesaffre and any shares that TGM may acquire in NattoPharma prior to the completion of the Offer. This means that TGM upon completion of the acquisition of the Additional Shares thereafter will transfer the Additional Shares to Lesaffre for the offer price, which currently is NOK 35.

Following the completion of the acquisition of the Additional Shares, TGM will hold 2 065 482 shares in NattoPharma, representing 10,41% of the total registered share capital and voting rights in NattoPharma, while primary insider Frode Bohan together with TGM and other related parties will control 3 976 789 shares in NattoPharma representing 20,04% of the total registered share capital and voting rights in NattoPharma, excluding 100 000 options NattoPharma that Frode Bohan has agreed to exercise and transfer to Lesaffre under the Offer.

TGM is also a related party to Kim Øien who is deputy board member in NattoPharma and consequently a primary insider. Following the completion of the acquisition of the Additional Shares Kim Øien together with TGM and other related parties will control 2 265 482 shares in NattoPharma representing 11,42% of the total registered share capital and voting rights in NattoPharma.